Compare Stocks → Kiss of death from Joe Biden (From Porter & Company) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDigital Media StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare ShareLink copied to clipboard. NASDAQ:EVAXNASDAQ:LIANNASDAQ:OCUPNYSEMKT:PHGE Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeEVAXEvaxion Biotech A/S$2.67+8.1%$3.80$2.26▼$13.82$14.45M-0.24383,155 shs53,865 shsLIANLianBio$0.32$0.31$0.27▼$4.99$35.01M0.231.04 million shs8,593 shsOCUPOcuphire Pharma$1.53-8.9%$1.72$1.50▼$4.58$39.66M0.35193,826 shs201,651 shsPHGEBiomX$0.34+3.1%$0.36$0.00▼$0.00$23.43M1.3268,601 shs76,439 shs10 Best Stocks to Own in 2024Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio. Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceEVAXEvaxion Biotech A/S-20.32%-25.60%-33.60%-19.54%-81.15%LIANLianBio0.00%-2.59%-0.57%+1.47%-87.00%OCUPOcuphire Pharma+1.82%-1.18%-0.30%-12.04%-56.59%PHGEBiomX-2.94%-5.90%-2.60%-10.79%-3.40%Kiss of death from Joe Biden (Ad)Biden cannot lose this election. A bombshell new documentary exposes how the D.C establishment has engineered an “electoral failsafe” that all but guarantees Democratic victory… not just in 2024 but every future election.I have uncovered a bombshell that changes everything… and threatens everything.MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationEVAXEvaxion Biotech A/S2.8457 of 5 stars3.55.00.00.02.81.70.6LIANLianBio0.6979 of 5 stars3.00.00.00.00.61.70.6OCUPOcuphire Pharma3.1668 of 5 stars3.64.00.00.03.31.71.3PHGEBiomX1.4915 of 5 stars3.50.00.00.00.61.71.3Analyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceEVAXEvaxion Biotech A/S3.00Buy$11.00311.99% UpsideLIANLianBio2.00Hold$5.331,546.09% UpsideOCUPOcuphire Pharma3.20Buy$18.751,125.49% UpsidePHGEBiomX3.00Buy$2.25570.24% UpsideCurrent Analyst RatingsLatest PHGE, EVAX, LIAN, and OCUP Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/4/2024EVAXEvaxion Biotech A/SHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$14.00 ➝ $14.005/28/2024PHGEBiomXLaidlawSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$2.505/21/2024PHGEBiomXHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$2.005/13/2024OCUPOcuphire PharmaCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy5/13/2024OCUPOcuphire PharmaCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$22.00 ➝ $18.005/13/2024OCUPOcuphire PharmaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$20.004/22/2024PHGEBiomXHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$2.004/3/2024EVAXEvaxion Biotech A/SHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$14.004/2/2024EVAXEvaxion Biotech A/SLADENBURG THALM/SH SHSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeNeutral ➝ Buy$8.003/20/2024EVAXEvaxion Biotech A/SHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$14.003/20/2024OCUPOcuphire PharmaAlliance Global PartnersSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$24.00 ➝ $20.00(Data available from 6/18/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookEVAXEvaxion Biotech A/S$70K206.35N/AN/A($1.17) per share-2.28LIANLianBioN/AN/AN/AN/A$2.71 per shareN/AOCUPOcuphire Pharma$19.05M2.08N/AN/A$2.20 per share0.70PHGEBiomXN/AN/AN/AN/A$0.70 per shareN/AProfitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateEVAXEvaxion Biotech A/S-$22.12M-$4.33N/AN/AN/AN/A-451.63%-99.11%8/16/2024 (Estimated)LIANLianBio-$110.29M-$0.81N/AN/AN/AN/A-33.17%-30.19%N/AOCUPOcuphire Pharma-$9.99M-$0.49N/AN/AN/A-59.44%-24.57%-22.22%8/9/2024 (Estimated)PHGEBiomX-$28.32M-$0.61N/AN/AN/AN/A-127.82%-56.50%N/ALatest PHGE, EVAX, LIAN, and OCUP EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/10/2024Q1 2024OCUPOcuphire Pharma-$0.18-$0.29-$0.11-$0.29$3.01 million$1.71 million3/27/2024Q4 2023EVAXEvaxion Biotech A/SN/A-$0.16-$0.16-$0.16N/A$0.07 millionDividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthEVAXEvaxion Biotech A/SN/AN/AN/AN/AN/ALIANLianBioN/AN/AN/AN/AN/AOCUPOcuphire PharmaN/AN/AN/AN/AN/APHGEBiomXN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioEVAXEvaxion Biotech A/SN/A1.181.18LIANLianBioN/A10.0610.06OCUPOcuphire PharmaN/A8.968.96PHGEBiomX0.512.842.84OwnershipInstitutional OwnershipCompanyInstitutional OwnershipEVAXEvaxion Biotech A/S11.04%LIANLianBio74.85%OCUPOcuphire Pharma14.97%PHGEBiomX40.57%Insider OwnershipCompanyInsider OwnershipEVAXEvaxion Biotech A/S41.64%LIANLianBio7.59%OCUPOcuphire Pharma8.70%PHGEBiomX4.21%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableEVAXEvaxion Biotech A/S495.41 million3.16 millionOptionableLIANLianBio163108.06 million99.86 millionNot OptionableOCUPOcuphire Pharma1425.92 million23.67 millionOptionablePHGEBiomX5869.81 million44.04 millionNot OptionablePHGE, EVAX, LIAN, and OCUP HeadlinesRecent News About These CompaniesMay 30, 2024 | globenewswire.comBiomX Inc. Receives Notice of Non-Compliance with NYSE American Continued Listing StandardsMay 30, 2024 | globenewswire.comBiomX to Present Phase 1b/2a Clinical Trial Data for BX004 at the 47th European Cystic Fibrosis Conference and at ASM Microbe 2024May 21, 2024 | globenewswire.comBiomX Reports First Quarter 2024 Financial Results and Provides Business and Program UpdatesMay 15, 2024 | globenewswire.comBiomX to Host First Quarter 2024 Financial Results Conference Call and Webcast on May 21, 2024May 14, 2024 | finance.yahoo.comBiomX to Present at the 2024 RBC Capital Markets Global Healthcare ConferenceApril 25, 2024 | investing.comBiomx Inc (PHGE_u)April 23, 2024 | globenewswire.comBiomX to Present Data from Phase 1b/2a Study of BX004 for the Treatment of Cystic Fibrosis Patients with Chronic Pulmonary Infections at the 34th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID 2024)April 19, 2024 | investing.comBiomX expands board with new director and audit chairApril 18, 2024 | globenewswire.comBiomX Announces the Appointment of Susan Blum to its Board of DirectorsApril 6, 2024 | uk.investing.comBiomX receives going concern note from auditorsApril 5, 2024 | zacks.comHere's Why BiomX (PHGE) Is a Great 'Buy the Bottom' Stock NowApril 4, 2024 | globenewswire.comBiomX Announces Compliance with NYSE Guidelines on Audit Opinion DisclosureApril 3, 2024 | msn.comU.S. Futures Dip in Pre-Market, May WTI and June Brent Crude Prices Edge HigherApril 3, 2024 | globenewswire.comBiomX Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business UpdateMarch 27, 2024 | globenewswire.comBiomX to Host Fourth Quarter and Full Year 2023 Financial Results Conference Call and Webcast on April 3rd, 2024March 18, 2024 | globenewswire.comBiomX Announces Closing of the Acquisition of Adaptive Phage Therapeutics and Concurrent $50 Million FinancingMarch 7, 2024 | markets.businessinsider.comBiomX Buy Rating Justified by Merger Synergy, Enhanced Financial Stability, and Promising Clinical TrialsMarch 7, 2024 | markets.businessinsider.comBiomX Acquisition and Clinical Trial Successes Prompt Buy Rating by Analyst Michael HigginsMarch 7, 2024 | prnewswire.comShareholder Alert: Ademi LLP investigates the transaction between BiomX Inc. and Adaptive Phage TherapeuticsMarch 6, 2024 | thepharmaletter.comBiomX announces Adaptive merger and financingNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesIntel's Secret Plan for a Double-Digit Stock Rally RevealedBy Gabriel Osorio-Mazilli | June 7, 2024View Intel's Secret Plan for a Double-Digit Stock Rally RevealedTop 3 Stocks Set to Soar with the AI-Driven Metaverse RevolutionBy Thomas Hughes | June 10, 2024View Top 3 Stocks Set to Soar with the AI-Driven Metaverse RevolutionTop 4 Fastest Growing S&P 500 Dividends: Buy, Sell, or Hold?By Thomas Hughes | June 12, 2024View Top 4 Fastest Growing S&P 500 Dividends: Buy, Sell, or Hold?Here's Why Analysts Boosted Walmart Stock's ValuationBy Gabriel Osorio-Mazilli | June 13, 2024View Here's Why Analysts Boosted Walmart Stock's ValuationCVS Health Stock Has a Silver Lining Called Value By Jea Yu | May 20, 2024View CVS Health Stock Has a Silver Lining Called Value Company DescriptionsEvaxion Biotech A/SNASDAQ:EVAXEvaxion Biotech A/S, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies. The company develops EVX-01, a cancer immunotherapy that is in clinical Phase IIb trial for metastatic melanoma; EVX-02, a DNA-based cancer immunotherapy that is in Phase 1/2a trial for adjuvant melanoma; and EVX-03, a DNA-based immunotherapy that is in pre-clinical stage for the treatment of various cancers. Its programs also include EVX-B1, EVX-B2, and EVX-V1, which are vaccines that are in pre-clinical stage for the treatment of bacterial and viral diseases. Evaxion Biotech A/S was incorporated in 2008 and is based in Horsholm, Denmark.LianBioNASDAQ:LIANLianBio, a biopharmaceutical company, engages in developing and commercializing medicines for cardiovascular, oncology, opthalmology, and inflammatory diseases in China and other Asian countries. The company develops mavacamten for the treatment of obstructive and non-obstructive hypertrophic cardiomyopathy, and heart failure with preserved ejection fraction; TP-03 for the treatment of Demodex blepharitis and meibomian gland disease; NBTXR3 for the treatment of head and neck squamous cell carcinoma, and solid tumor; Infigratinib for the treatment of second-line and first-line cholangiocarcinoma, and gastric cancers; BBP-398 for solid tumors; Omilancor and NX-13 for ulcerative colitis and Crohn's disease; LYR-210 for chronic rhinosinusitis; and Sisunatovir for respiratory syncytical virus. It has a partnership with Tarsus Pharmaceuticals, Inc. to develop and commercialize TP-03 for the treatment of Demodex blepharitis; and Nanobiotix S.A. to develop and commercialize NBTXR3, a radioenhancer designed to be injected directly into a malignant tumor prior to standard radiotherapy. The company was incorporated in 2019 and is headquartered in Princeton, New Jersey.Ocuphire PharmaNASDAQ:OCUPOcuphire Pharma, Inc., a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders. The company offers Phentolamine Ophthalmic Solution for reversal of mydriasis, as well as is in Phase III clinical trials for presbyopia and dim light or night vision disturbances. Its lead retinal product candidate is APX3330, a small-molecule inhibitor of reduction oxidation effector factor-1 protein that has completed Phase II clinical trial for the treatment of diabetic retinopathy. The company also develops APX2009 and APX2014 that are preclinical product candidates for retina indications. The company was founded in 2018 and is headquartered in Farmington Hills, Michigan.BiomXNYSEMKT:PHGEBiomX Inc., a clinical-stage biopharmaceutical company, develops products using natural and engineered phage technologies designed to target and kill specific harmful bacteria associated with chronic disease. It is developing BX211, a phage therapy, which is in phase 2 clinical study for the treatment of diabetic foot osteomyelitis. The company's product pipeline also includes BX004, a phage therapy for cystic fibrosis patients with chronic pulmonary infections caused by Pseudomonas aeruginosa that is in Phase 1b/2a clinical trials. BiomX Inc. was founded in 2015 and is headquartered in Ness Ziona, Israel. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.